Gibbs Wealth Management’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
Other funds holding VRTX
Gibbs Wealth Management's VRTX Position: Q1 2026 in Review
Gibbs Wealth Management increased its Vertex Pharmaceuticals (VRTX) stake by 357% in Q1 2026, buying an estimated $2.06M and bringing the position to 5,647 shares worth $2.52M. The position accounts for 0.33% of the portfolio, ranked #48.
Gibbs Wealth Management first reported a position in VRTX in Q4 2024 and has held it in 6 quarters since. 1,699 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.
- Gibbs Wealth Management held 5,647 shares of Vertex Pharmaceuticals worth $2.52M as of Q1 2026.
- Gibbs Wealth Management bought 4,412 Vertex Pharmaceuticals shares in Q1 2026, an estimated $2.06M.
- Vertex Pharmaceuticals made up 0.33% of Gibbs Wealth Management's portfolio in Q1 2026, its #48 holding.
- Gibbs Wealth Management first reported a position in Vertex Pharmaceuticals in Q4 2024 and has held it in 6 quarters since.
- 1,699 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.
Based on Gibbs Wealth Management's 13F filing for Q1 2026, filed 13 May 2026.